论文部分内容阅读
目的对比观察阿昔洛韦与干扰素治疗儿童EB病毒感染的临床效果。方法根据中心随机系统法将EB病毒感染患儿72例分为阿昔洛韦组和干扰素组。治疗后对比2组EB病毒感染控制率、退热时间、淋巴结肿大、肝脾肿大消退时间及咽峡炎缓解时间,治疗前后EB-DNA定量和异型淋巴细胞比例。结果阿昔洛韦组EB病毒感染控制率高于干扰素组,差异有统计学意义(P<0.05);退热时间、淋巴结肿大、肝脾肿大消退时间及咽峡炎缓解时间均短于干扰素组,差异均有统计学意义(P<0.05);治疗前2组EB-DNA定量和异型淋巴细胞比例比较差异无统计学意义(P>0.05),治疗后2组EB-DNA定量和异型淋巴细胞比例均降低,且阿昔洛韦组低于干扰素组,差异均有统计学意义(P<0.05)。结论阿昔洛韦治疗儿童EB病毒感染效果确切,可有效促进患儿发热、淋巴结肿大、肝脾肿大等症状的消退,降低EB-DNA定量和异型淋巴细胞比例,对患儿预后有益,且用药安全性高,值得临床推广应用。
Objective To compare the clinical efficacy of acyclovir and interferon in the treatment of children with Epstein-Barr virus infection. Methods 72 cases of children with Epstein-Barr virus infection were divided into acyclovir group and interferon group according to the central randomized system method. After treatment, the control rate of EBV infection, antipyretic time, lymph node enlargement, remission time of hepatosplenomegaly and angina were compared between the two groups. The ratio of EB-DNA quantitive and atypical lymphocytes before and after treatment was compared. Results The control rate of Epstein-Barr virus infection in acyclovir group was higher than that in interferon group (P <0.05). The antipyretic time, lymph node enlargement, subsidence of hepatosplenomegaly and angina were all shortened In the interferon group, the difference was statistically significant (P <0.05); before treatment, EB-DNA quantitative and atypical lymphocytes ratio was no significant difference (P> 0.05), after treatment, EB-DNA quantification And the ratio of atypical lymphocytes decreased, and the acyclovir group was lower than the interferon group, the differences were statistically significant (P <0.05). Conclusion Aciclovir treatment of children with Epstein-Barr virus infection is effective and can effectively promote children with fever, lymph nodes, hepatosplenomegaly and other symptoms subsided, reduce EB-DNA quantitative and atypical lymphocyte ratio, the prognosis of children with good, And medication safety, it is worth to promote clinical application.